Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART. / Mens, Helene; Fjordside, Lasse; Fonager, Jannik; Gerstoft, Jan.

In: Infectious Disease Reports, Vol. 14, No. 4, 2022, p. 501-504.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Mens, H, Fjordside, L, Fonager, J & Gerstoft, J 2022, 'Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART', Infectious Disease Reports, vol. 14, no. 4, pp. 501-504. https://doi.org/10.3390/idr14040053

APA

Mens, H., Fjordside, L., Fonager, J., & Gerstoft, J. (2022). Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART. Infectious Disease Reports, 14(4), 501-504. https://doi.org/10.3390/idr14040053

Vancouver

Mens H, Fjordside L, Fonager J, Gerstoft J. Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART. Infectious Disease Reports. 2022;14(4):501-504. https://doi.org/10.3390/idr14040053

Author

Mens, Helene ; Fjordside, Lasse ; Fonager, Jannik ; Gerstoft, Jan. / Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART. In: Infectious Disease Reports. 2022 ; Vol. 14, No. 4. pp. 501-504.

Bibtex

@article{0562a91138434f19a791c3815454fae8,
title = "Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART",
abstract = "HIV-1 resistance towards integrase inhibitors is a potential threat of the success of HIV-1 combination treatment. G118R is a rare drug resistance mutation conferring pan-integrase resistance. Here, we describe the occurrence of G118R in a HIV-1 subtype-B-positive individual with major compliance problems, detected while the patient was on dolutegravir-based cART. We speculate the pre-selection of M184I/V aided the occurrence of G118R in this case, and discuss the robustness of dolutegravir-based therapies.",
keywords = "drug resistance, HIV-1, integrase inhibitors",
author = "Helene Mens and Lasse Fjordside and Jannik Fonager and Jan Gerstoft",
note = "Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2022",
doi = "10.3390/idr14040053",
language = "English",
volume = "14",
pages = "501--504",
journal = "Infectious Disease Reports",
issn = "2036-7430",
publisher = "PagePress Publications",
number = "4",

}

RIS

TY - JOUR

T1 - Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART

AU - Mens, Helene

AU - Fjordside, Lasse

AU - Fonager, Jannik

AU - Gerstoft, Jan

N1 - Publisher Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland.

PY - 2022

Y1 - 2022

N2 - HIV-1 resistance towards integrase inhibitors is a potential threat of the success of HIV-1 combination treatment. G118R is a rare drug resistance mutation conferring pan-integrase resistance. Here, we describe the occurrence of G118R in a HIV-1 subtype-B-positive individual with major compliance problems, detected while the patient was on dolutegravir-based cART. We speculate the pre-selection of M184I/V aided the occurrence of G118R in this case, and discuss the robustness of dolutegravir-based therapies.

AB - HIV-1 resistance towards integrase inhibitors is a potential threat of the success of HIV-1 combination treatment. G118R is a rare drug resistance mutation conferring pan-integrase resistance. Here, we describe the occurrence of G118R in a HIV-1 subtype-B-positive individual with major compliance problems, detected while the patient was on dolutegravir-based cART. We speculate the pre-selection of M184I/V aided the occurrence of G118R in this case, and discuss the robustness of dolutegravir-based therapies.

KW - drug resistance

KW - HIV-1

KW - integrase inhibitors

U2 - 10.3390/idr14040053

DO - 10.3390/idr14040053

M3 - Journal article

C2 - 35893472

AN - SCOPUS:85134366152

VL - 14

SP - 501

EP - 504

JO - Infectious Disease Reports

JF - Infectious Disease Reports

SN - 2036-7430

IS - 4

ER -

ID: 324815316